-
公开(公告)号：US09375471B2
公开(公告)日：2016-06-28
申请号：US13790948
申请日：2013-03-08
Applicant: Novartis AG
Inventor： Barbara Baudner , Derek O'Hagan , Manmohan Singh , Simone Bufali
CPC classification number: A61K39/39 , A61K9/107 , A61K39/0018 , A61K39/13 , A61K2039/55505 , A61K2039/55511 , A61K2039/55566 , A61K2039/55572 , C12N7/00 , C12N2770/32634 , Y02A50/466
Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
Abstract translation: 本发明通过在其中包含TLR激动剂来改善TdaP疫苗。 该激动剂可以提供更强的保护，更持久的保护和/或可以减少实现特定免疫应答所需的抗原的量。
-
公开(公告)号：US20150202277A1
公开(公告)日：2015-07-23
申请号：US14420229
申请日：2013-08-29
Applicant: NOVARTIS AG
Inventor： Fabio Bagnoli , Simone Bufali , Simona Cianetti , Anna Coslovi , Guido Grandi , Mikkel Nissum , Michele Pallaoro , Silvana Savino , Michele Sotgiu
IPC: A61K39/085 , A61K39/39
CPC classification number: A61K39/085 , A61K39/39 , A61K2039/55511 , A61K2039/70 , C07K14/3156
Abstract: Elimination of disulphide bond formation of cysteine-containing S.aureus antigens enhances antigen stability. The invention provides a composition comprising variant forms of cysteine-containing S.aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.
Abstract translation: 消除含半胱氨酸的金黄色葡萄球菌抗原的二硫键形成增强了抗原的稳定性。 本发明提供包含替代，删除或修饰半胱氨酸残基的点突变的含半胱氨酸的金黄色葡萄球菌抗原的变体形式的组合物。
-
3.发明申请公开(公告)号：US20150132339A1
公开(公告)日：2015-05-14
申请号：US14381090
申请日：2013-03-07
Applicant: NOVARTIS AG
Inventor： Simone Bufali , Paolo Costantino , Michele Pallaoro , Derek O'hagan , Rino Rappuoli , Manmohan Singh
IPC: A61K39/09 , A61K33/08 , A61K31/4745 , A61K39/39
CPC classification number: A61K39/092 , A61K31/4375 , A61K31/4745 , A61K33/06 , A61K33/08 , A61K39/39 , A61K45/06 , A61K2039/55505 , A61K2039/55511 , A61K2039/6037 , A61K2300/00
Abstract: The efficacy of S. pneumoniae vaccines can be enhanced by adjuvanting S. pneumoniae saccharide and/or protein antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The S. pneumoniae antigen can also be adsorbed to the metal salt.
Abstract translation: 通过用TLR激动剂（优选TLR7激动剂）和不溶性金属盐（优选铝盐）的混合物佐剂肺炎链球菌糖和/或蛋白质抗原来增强肺炎链球菌疫苗的功效。 TLR激动剂通常被吸附到金属盐上。 肺炎链球菌抗原也可以被吸附到金属盐上。
-
公开(公告)号：US20150125486A1
公开(公告)日：2015-05-07
申请号：US14381438
申请日：2013-03-08
Applicant: Novartis AG
Inventor： Simone Bufali , Barbara Baudner , Derek O'Hagan , Manmohan Singh
CPC classification number: A61K39/39 , A61K39/0018 , A61K39/092 , A61K39/095 , A61K39/102 , A61K39/12 , A61K39/13 , A61K39/395 , A61K45/06 , A61K2039/55505 , A61K2039/55572 , A61K2039/70 , C12N7/00 , C12N2730/10134 , C12N2770/32634 , Y02A50/466 , A61K2300/00
Abstract: An immunogenic composition comprising a diphtheria toxoid, a tetanus toxoid, a pertussis toxoid, an aluminium salt adjuvant, and a TLR4 agonist. Preferably, the TLR4 agonist and/or at least one of the toxoids is/are adsorbed to the aluminium salt adjuvant.
Abstract translation: 包含白喉类毒素，破伤风类毒素，百日咳类毒素，铝盐佐剂和TLR4激动剂的免疫原性组合物。 优选地，TLR4激动剂和/或至少一种类毒素被吸附到铝盐佐剂上。
-
-
-
Search Results
4
records
(took 0.016 seconds)
